These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19698704)

  • 1. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
    Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
    Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
    Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
    Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism.
    Elliott E; Atlas R; Lange A; Ginzburg I
    Eur J Neurosci; 2005 Sep; 22(5):1081-9. PubMed ID: 16176349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.
    Wang HH; Li HL; Liu R; Zhang Y; Liao K; Wang Q; Wang JZ; Liu SJ
    J Alzheimers Dis; 2010; 21(1):167-79. PubMed ID: 20413892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
    Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
    Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
    J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
    Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
    Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
    Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation.
    Shim SB; Lim HJ; Chae KR; Kim CK; Hwang DY; Jee SW; Lee SH; Sin JS; Leem YH; Lee SH; Cho JS; Lee HH; Choi SY; Kim YK
    Neuroscience; 2007 May; 146(2):730-40. PubMed ID: 17337327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau.
    Nuydens R; Van Den Kieboom G; Nolten C; Verhulst C; Van Osta P; Spittaels K; Van den Haute C; De Feyter E; Geerts H; Van Leuven F
    Neurobiol Dis; 2002 Feb; 9(1):38-48. PubMed ID: 11848683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
    Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH
    Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
    Avila J
    FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.